CLAIMS

1. A compound of Formula (I):



(I)

wherein:

X^1 is N;

X^2 is selected from the group consisting of CH and CF;

R^1 is selected from the group consisting of cyano, C_{1-2} alkyl, and C_{1-2} haloalkyl;

R^2 and R^3 together with the carbon atom to which they are attached form cyclopropyl;

Ar is 1,2,4-thiadiazolyl or 1,3,4-thiadiazolyl;

R^4 is selected from the group consisting of C_{1-3} alkyl, C_{1-3} haloalkyl, hydroxyC_{1-3}alkyl, -C(O)H, and cyano;

R^5 and R^6 are each absent;

R^7 is hydrogen;

ring B is heterocyclyl, fused heterocyclyl, spiro heterocyclyl, or bridged heterocyclyl, wherein heterocyclyl, fused heterocyclyl, spiro heterocyclyl, and bridged heterocyclyl of ring B are each substituted with R^a, R^b, and/or R^c;

R^a is hydrogen, C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, halo, C_{1-6} haloalkyl, C_{1-6} haloalkoxy, hydroxyC_{1-6} alkyl, heteroaryl, heterocyclyl, -C(O)R^d (where R^d is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, phenyl, heteroaryl, or heterocyclyl), -C(O)OR^e (where R^e is hydrogen or C_{1-6} alkyl), or -C(O)N$R^f R^g$ (where R^f and R^g are each independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, aminoC_{1-6} alkyl, and hydroxyC_{1-6} alkyl; or R^f and R^g together with the nitrogen atom to which they are attached form heterocyclyl), or -$S(O)_2$N$R^h R^i$ (where R^h and R^i are each independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, aminoC_{1-6} alkyl, and hydroxyC_{1-6} alkyl; or R^h and R^i together with the nitrogen atom to which they are attached form heterocyclyl); and

R^b and R^c are each independently selected from hydrogen, C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, halo, C_{1-6} haloalkyl, and C_{1-6} haloalkoxy, wherein

heteroaryl and heterocyclyl of R^a, phenyl, heteroaryl, and heterocyclyl of R^d, heterocyclyl formed by R^f and R^g combining with the nitrogen to which they are attached, and heterocyclyl formed by R^h and R^i combining with the nitrogen to which they are attached are each independently unsubstituted or substituted with one, two, or three substituents selected from C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, halo, C_{1-6} haloalkyl, and C_{1-6} haloalkoxy; or

a pharmaceutically acceptable salt thereof.

2. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, wherein X^2 is CH.

3. The compound of claim **1** or **2**, or a pharmaceutically acceptable salt thereof, wherein R^1 is cyano.

4. The compound of claim **1** or **2**, or a pharmaceutically acceptable salt thereof, wherein R^1 is methyl.

5. The compound of any one of claims **1** to **4**, or a pharmaceutically acceptable salt thereof, wherein Ar is 1,3,4-thiadiazol-2-yl.

6. The compound of any one of claims **1** to **5**, or a pharmaceutically acceptable salt thereof, wherein R^4 is methyl, ethyl, difluoromethyl, trifluoromethyl, cyano, or –C(O)H.

7. The compound of any one of claims **1** to **5**, or a pharmaceutically acceptable salt thereof, wherein R^4 is C_{1-3} haloalkyl.

8.The compound of any one of claims **1** to **7**, or a pharmaceutically acceptable salt thereof, wherein R^4 is difluoromethyl.

9.The compound of any one of claims 1 to **8**, or a pharmaceutically acceptable salt thereof, wherein ring B is heterocyclyl substituted with R^a, R^b, and/or R^c.

10. The compound of claim **9**, or a pharmaceutically acceptable salt thereof, wherein ring B is morpholinyl, 1,1-dioxothiomorpholinyl, azetinyl, pyrrolidinyl, piperidinyl, 6-oxo-1,6-

dihydropyridinyl, or piperazinyl, wherein each morpholinyl, 1,1-dioxothiomorpholinyl, azetinyl, pyrrolidinyl, piperidinyl, 6-oxo-1,6-dihydropyridinyl, and piperazinyl is independently substituted with R^a, R^b, and/or R^c;

R^a is hydrogen, C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, halo, C_{1-6} haloalkyl, hydroxyC_{1-6} alkyl, heteroaryl, -C(O)R^d (where R^d is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, phenyl, heteroaryl, or heterocyclyl), -C(O)OR^e (where R^e is hydrogen or C_{1-6} alkyl), -C(O)N$R^f R^g$ (where R^f and R^g are each independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, aminoC_{1-6} alkyl, and hydroxyC_{1-6} alkyl); and

R^b and R^c are each independently selected from hydrogen, C_{1-6} alkyl, hydroxy, C_{1-6} alkoxy, halo, C_{1-6} haloalkyl, and C_{1-6} haloalkoxy, wherein

heteroaryl of R^a, phenyl, heteroaryl, and heterocyclyl of R^d are each independently unsubstituted or substituted with one, two, or three substituents independently selected from C_{1-6} alkyl and C_{1-6} haloalkyl.

11. The compound of claim **10**, or a pharmaceutically acceptable salt thereof, wherein R^a is hydrogen, C_{1-6} alkyl, hydroxy, halo, C_{1-6} haloalkyl, hydroxyC_{1-6} alkyl, heteroaryl, -C(O)R^d (where R^d is hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{3-6} cycloalkyl, phenyl, heteroaryl, or heterocyclyl), -C(O)OR^e (where R^e is C_{1-6} alkyl), or -C(O)N$R^f R^g$ (where R^f and R^g are each independently selected from hydrogen, C_{1-6} alkyl, C_{1-6} haloalkyl, and aminoC_{1-6} alkyl); and

R^b and R^c are each independently selected from hydrogen, C_{1-6} alkyl, and halo, wherein

heteroaryl of R^a and heterocyclyl of R^d are each independently unsubstituted or substituted with one, two, or three substituents independently selected from C_{1-6} alkyl and C_{1-6} haloalkyl.

12. The compound of any one of claims **9** to **11**, or a pharmaceutically acceptable salt thereof, wherein ring B is piperazinyl substituted with R^a, R^b, and/or R^c.

13. The compound of any one of claims **1** to **12**, or a pharmaceutically acceptable salt thereof, wherein

R^a is hydrogen, C_{1-6} alkyl, hydroxy, halo, C_{1-6} haloalkyl, or hydroxyC_{1-6} alkyl; and

R^b and R^c are each independently hydrogen, C_{1-6} alkyl, or halo.

14. The compound of any one of claims **1** to **12**, or a pharmaceutically acceptable salt thereof, wherein

R^a is hydrogen or C_{1-6} alkyl; and

R^b and R^c are each independently hydrogen, C_{1-6} alkyl, or halo.

15. The compound of any one of claims **9** to **14**, or a pharmaceutically acceptable salt thereof, wherein R^a is attached to the atom of ring B that is para to the ring atom attaching ring B to the remainder of the molecule.

16. The compound of any one of claims 1 to **8**, or a pharmaceutically acceptable salt thereof, wherein ring B is bicyclic heterocyclyl, fused heterocyclyl, spiro heterocyclyl, or bridged heterocyclyl, wherein each bicyclic heterocyclyl, fused heterocyclyl, spiro heterocyclyl, and bridged heterocyclyl is independently substituted with R^a, R^b, and/or R^c.

17. The compound of claim **16**, or a pharmaceutically acceptable salt thereof, wherein ring B is 2-oxaspiro[3.5]non-6-en-7-yl, 2-oxaspiro[3.5]non-7-yl, 2-oxa-8-azaspiro[4.5]dec-8-yl, 9-oxa-3-azaspiro[5.5]undec-3-yl, 2-oxa-6-azaspiro[3.4]oct-6-yl, 1-oxa-7-azaspiro[3.5]non-7-yl, 1-oxa-8-azaspiro[4.5]dec-8-yl, 6-oxa-2-azaspiro[3.3]hept-2-yl, 2,8-diazaspiro[4.5]dec-8-yl, 7-oxa-3-azabicyclo[3.3.0]oct-3-yl, 8-oxa-3-azabicyclo[4.3.0]non-3-yl, 2-oxa-6-azaspiro[3.5]non-6-yl, 7-oxo-3,6,8-triazabicyclo[4.3.0]non-3-yl, 3-pyrrolino[3,4-c]pyrazol-2-yl, 3,6-diazabicyclo[3.1.1]hept-3-yl, 2,7-diazaspiro[3.5]non-7-yl, wherein each 2-oxaspiro[3.5]non-6-en-7-yl, 2-oxaspiro[3.5]non-7-yl, 2-oxa-8-azaspiro[4.5]dec-8-yl, 9-oxa-3-azaspiro[5.5]undec-3-yl, 2-oxa-6-azaspiro[3.4]oct-6-yl, 1-oxa-7-azaspiro[3.5]non-7-yl, 1-oxa-8-azaspiro[4.5]dec-8-yl, 6-oxa-2-azaspiro[3.3]hept-2-yl, 2,8-diazaspiro[4.5]dec-8-yl, 7-oxa-3-azabicyclo[3.3.0]oct-3-yl, 8-oxa-3-azabicyclo[4.3.0]non-3-yl, 2-oxa-6-azaspiro[3.5]non-6-yl, 7-oxo-3,6,8-triazabicyclo[4.3.0]non-3-yl, 3-pyrrolino[3,4-c]pyrazol-2-yl, 3,6-diazabicyclo[3.1.1]hept-3-yl, and 2,7-diazaspiro[3.5]non-7-yl is optionally substituted with R^a, wherein R^a is C_{1-6} alkyl.

18. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, wherein

X^2 is CH;

R^1 is methyl;

Ar is 1,3,4-thiadiazol-2-yl;

R^4 is difluoromethyl;

ring B is piperazinyl, substituted with R^a, R^b, and/or R^c;

R^a is hydrogen or C_{1-6} alkyl; and

R^b and R^c are each independently selected from hydrogen, C_{1-6} alkyl, and halo.

19. The compound of claim **1**, or a pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(2-oxaspiro[3.5]non-6-en-7-yl)-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(2-oxaspiro[3.5]non-7-yl)-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(2-oxa-7-azaspiro[3.5]non-7-yl)(1H-indazol-6-yl)}sulfonyl)(methylcyclopropyl)amine;

[4-(1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-6-{[(methylcyclopropyl)amino]sulfonyl}(1H-indazol-4-yl))piperazinyl]-N,N-dimethylcarboxamide;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(2-oxa-7-azaspiro[3.5]non-7-yl)-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({4-((2R)-2-methylmorpholin-4-yl)-1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(4-hydroxypiperidyl)-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-[4-(2-methylpropanoyl)piperazinyl]indol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(2-oxa-8-azaspiro[4.5]dec-8-yl)-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(9-oxa-3-azaspiro[5.5]undec-3-yl)-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

[4-(1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-6-{[(cyanocyclopropyl)amino] sulfonyl}(1H-indazol-4-yl))(1,4-diazaperhydroepinyl)]-N-methylcarboxamide;

[4-(1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-6-{[(cyanocyclopropyl)amino] sulfonyl}(1H-indazol-4-yl))piperazinyl]-N-ethyl-N-methylcarboxamide;

1-[({4-[4-(azetidinylcarbonyl)piperazinyl]-1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(2-oxa-6-azaspiro[3.4]oct-6-yl)-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

[(2R)-4-(1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-6-{[(cyanocyclopropyl) amino]sulfonyl}(1H-indazol-4-yl))-2-methylpiperazinyl]-N,N-dimethylcarboxamide;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-[4-(4-methyl(1,2,4-triazol-3-yl))piperazinyl]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({4-[(1S,5R)-8-(2-methylpropanoyl)-3,8-diazabicyclo[3.2.1]oct-3-yl]-1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-1H-indazol-6-yl}sulfonyl)amino]cyclopropane carbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-[4-(2-methylpropanoyl) piperazinyl]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-[4-(2,2-dimethylpropanoyl) piperazinyl]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

[1-(1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-6-{[(cyanocyclopropyl)amino] sulfonyl}(1H-indazol-4-yl))(4-piperidyl)]-N-methylcarboxamide;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(1-oxa-7-azaspiro[3.5]non-7-yl)-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(1,4-oxazaperhydroepin-4-yl)-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

[4-(1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-6-{[(cyanocyclopropyl)amino]sulfonyl}(1H-indazol-4-yl))piperazinyl]-N,N-dimethylcarboxamide;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(1-oxa-8-azaspiro[4.5]dec-8-yl)-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(6-oxa-2-azaspiro[3.3]hept-2-yl)-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(2-methyl-2,8-diazaspiro[4.5]dec-8-yl)-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-[4-(hydroxymethyl)piperidyl]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({4-((1S,5R)-7-oxa-3-azabicyclo[3.3.0]oct-3-yl)-1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(4-formylpiperazinyl)-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({4-(4-acetylpiperazinyl)-1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

[1-(1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-6-{[(cyanocyclopropyl)amino] sulfonyl}(1H-indazol-4-yl))(4-piperidyl)]-N,N-dimethylcarboxamide;

N-(1-cyanocyclopropyl)-1-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-4-(1,1-dioxidothiomorpholino)-1H-indazole-6-sulfonamide;

[1-(1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-6-{[(cyanocyclopropyl)amino] sulfonyl}(1H-indazol-4-yl))pyrrolidin-3-yl]-N-methylcarboxamide;

[1-(1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-6-{[(cyanocyclopropyl)amino] sulfonyl}(1H-indazol-4-yl))pyrrolidin-3-yl]-N,N-dimethylcarboxamide;

[1-(1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-6-{[(cyanocyclopropyl)amino] sulfonyl}(1H-indazol-4-yl))azetidin-3-yl]-N,N-dimethylcarboxamide;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(*cis*-8-oxa-3-azabicyclo-[4.3.0]non-3-yl)-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-[4-(pyrrolidinylcarbonyl)-piperazinyl]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

methyl 4-(1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-6-{[(cyanocyclopropyl) amino]sulfonyl}-1H-indazol-4-yl)piperazinecarboxylate;

1-[({4-((1S)-7-oxo-3,6-diazabicyclo[4.3.0]non-3-yl)-1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({4-((1R)-7-oxo-3,6-diazabicyclo[4.3.0]non-3-yl)-1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({4-((1R)-7-oxo-8-oxa-3,6-diazabicyclo[4.3.0]non-3-yl)-1-[5-(difluoromethyl) (1,3,4-thiadiazol-2-yl)]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({4-((1S)-7-oxo-8-oxa-3,6-diazabicyclo[4.3.0]non-3-yl)-1-[5-(difluoromethyl) (1,3,4-thiadiazol-2-yl)]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(4-methyl(1,4-diazaperhydro-epinyl))-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-[4-(difluoromethyl)piperidyl]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(2-oxa-6-azaspiro[3.5]non-6-yl)-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-[4-(cyclopentylcarbonyl) piperazinyl]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

N-(2,2-difluoroethyl)[4-(1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-6-{[(cyano-cyclopropyl)amino]sulfonyl}(1H-indazol-4-yl))piperazinyl]-N-methylcarboxamide;

1-{[(4-{4-[((3S)-1-methylpyrrolidin-3-yl)carbonyl]piperazinyl}-1-[5-(difluoro methyl)(1,3,4-thiadiazol-2-yl)]-1H-indazol-6-yl)sulfonyl]amino}cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-[4-(1-methylimidazol-2-yl)piperazinyl]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(7-oxa-3,9-diazabicyclo-[3.3.1]non-3-yl)-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({4-(8-methyl-7-oxo-3,6,8-triazabicyclo[4.3.0]non-3-yl)-1-[5-(difluoromethyl)-(1,3,4-thiadiazol-2-yl)]-1H-indazol-6-yl}sulfonyl)amino]cyclopropane carbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(5-methyl(3-pyrrolino[3,4-c]pyrazol-2-yl))-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

4-(6-(N-(1-cyanocyclopropyl)sulfamoyl)-1-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1H-indazol-4-yl)-N-methylpiperazine-1-carboxamide;

1-(6-(N-(1-cyanocyclopropyl)sulfamoyl)-1-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-1H-indazol-4-yl)-N-methylazetidine-3-carboxamide;

[4-(1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-6-{[(cyanocyclopropyl)amino] sulfonyl}(1H-indazol-4-yl))piperazinyl]-N-[2-(dimethylamino)ethyl]-N-methylcarboxamide;

[4-(1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-6-{[(cyanocyclopropyl)amino] sulfonyl}(1H-indazol-4-yl))piperazinyl]-N-methyl-N-propylcarboxamide;

[4-(1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-6-{[(cyanocyclopropyl)amino]-sulfonyl}(1H-indazol-4-yl))(1,4-diazaperhydroepinyl)]-N,N-dimethylcarboxamide;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-[4-(3-methyl(2-pyridyl))-piperazinyl]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-[4-(cyclopropylcarbonyl) piperazinyl]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-[4-(cyclobutylcarbonyl)piperazinyl]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({4-[(3R)-3-methyl-4-(2-methylpropanoyl)piperazinyl]-1-[5-(difluoromethyl) (1,3,4-thiadiazol-2-yl)]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

[(2S)-4-(1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-6-{[(cyanocyclopropyl) amino]sulfonyl}(1H-indazol-4-yl))-2-methylpiperazinyl]-N,N-dimethylcarboxamide;

1-{[(1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-{4-[(1-methyl(4-piperidyl))-carbonyl]piperazinyl}-1H-indazol-6-yl)sulfonyl]amino}cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-[4-(4-methyl(3-pyridyl)) piperazinyl]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

[4-(1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-6-{[(cyanocyclopropyl)amino] sulfonyl}(1H-indazol-4-yl))piperazinyl]-N-methyl-N-(2,2,2-trifluoroethyl)carboxamide;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-[4-(2-pyridylcarbonyl) piperazinyl]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({4-[(3S)-3-methyl-4-(2-methylpropanoyl)piperazinyl]-1-[5-(difluoromethyl) (1,3,4-thiadiazol-2-yl)]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({4-[*cis*-3,5-dimethyl-4-(2-methylpropanoyl)piperazinyl]-1-[5-(difluoromethyl)-(1,3,4-thiadiazol-2-yl)]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-{[(4-{4-[((2R)-1-methylpyrrolidin-2-yl)carbonyl]piperazinyl}-1-[5-(difluoro methyl)(1,3,4-thiadiazol-2-yl)]-1H-indazol-6-yl)sulfonyl]amino}cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-[6-(2-methylpropanoyl)-3,6-diazabicyclo[3.1.1]hept-3-yl]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(2-methyl-2,7-diazaspiro-[3.5]non-7-yl)-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(4-(2-pyridyl)piperazinyl)-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(4-(3-pyridyl)piperazinyl)-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(4-pyridazin-3-ylpiperazinyl)-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-[4-(phenylcarbonyl)piperazinyl] -1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-(5-methyl(1,3,4-thiadiazol-2-yl))-4-[4-(2-methylpropanoyl)piperazinyl]-1H-indazol-6-yl} sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-morpholin-4-yl-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-pyrrolidinyl-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(4-methylpiperazinyl)-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

(S)-N-(1-cyanocyclopropyl)-1-(5-(difluoromethyl)-1,3,4-thiadiazol-2-yl)-4-(2-methylmorpholino)-1H-indazole-6-sulfonamide;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(4-fluoropiperidyl)-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-(4,4-difluoropiperidyl)-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile;

1-({[4-((3R)-4-{[1-(2,2-difluoroethyl)(4-piperidyl)]carbonyl}-3-methyl piperazinyl)-1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-1H-indazol-6-yl]sulfonyl}amino) cyclopropanecarbonitrile;

1-({[4-(4-{[1-(2,2-difluoroethyl)(4-piperidyl)]carbonyl}piperazinyl)-1-[5-(difluoro-methyl)(1,3,4-thiadiazol-2-yl)]-1H-indazol-6-yl]sulfonyl}amino)cyclopropane carbonitrile;

1-{[(4-{(3R)-3-methyl-4-[(methylcyclopropyl)carbonyl]piperazinyl}-1-[5-(difluoro-methyl)(1,3,4-thiadiazol-2-yl)]-1H-indazol-6-yl)sulfonyl]amino}cyclopropane carbonitrile;

1-{[(4-{(3R)-3-methyl-4-[(methylcyclobutyl)carbonyl]piperazinyl}-1-[5-(difluoro-methyl)(1,3,4-thiadiazol-2-yl)]-1H-indazol-6-yl)sulfonyl]amino}cyclopropane carbonitrile;

1-[({4-[(3R)-3-methyl-4-(2-methylbutanoyl)piperazinyl]-1-[5-(difluoromethyl)-(1,3,4-thiadiazol-2-yl)]-1H-indazol-6-yl}sulfonyl)amino]cyclopropane carbonitrile;

1-{[(1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-{4-[(methylcyclopropyl) carbonyl]piperazinyl}-1H-indazol-6-yl)sulfonyl]amino}cyclopropanecarbonitrile;

1-{[(1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-{4-[(methylcyclobutyl) carbonyl]piperazinyl }-1H-indazol-6-yl)sulfonyl]amino}cyclopropanecarbonitrile; and

1-[({1-[5-(difluoromethyl)(1,3,4-thiadiazol-2-yl)]-4-[4-(2-methylbutanoyl) piperazinyl]-1H-indazol-6-yl}sulfonyl)amino]cyclopropanecarbonitrile.

20. A pharmaceutical composition comprising a compound of any one of claims **1** to **19**, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

21. Use of the compound of any one of claims **1** to **19**, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim **20** in the manufacture of a medicament for treating a cancer in a subject in need thereof.

22. The use of claim **21**, wherein the subject has also received surgery, radiotherapy, or chemotherapy to treat the cancer.

23. A combination for use in treating a cancer in a subject in need thereof, wherein the combination comprises:

(a) the compound of any one of claims **1** to **19**, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim **20**, and

(b) another anti-tumour agent;

and wherein the subject is to be administered simultaneous, sequential or separate dosing of the individual components of the combination.

24. The use of any one of claims **21** to **22**, or the combination for use according to claim 23, wherein the cancer is lung cancer, colon cancer, breast cancer, ovarian cancer, prostate cancer, liver cancer, pancreatic cancer, brain cancer, or skin cancer.